Quality of life with pharmacological treatment in patients with benign prostatic enlargement: Results from the evolution european prospective multicenter multi-national registry study
World Journal of Urology May 07, 2020
Bhatt NR, Davis NF, Witjes WP, et al. - In this study, the impact of pharmacological treatment of lower urinary tract symptoms due to benign prostate enlargement (LUTS/BPE) on disease specific and generic quality of life (QOL) measures was investigated. Researchers performed an European prospective, multicenter multi-national, observational registry collecting real-life clinical data over 2 years on the management of LUTS/BPE in primary and secondary care. Disease-specific QOL was evaluated applying questionnaires such as IPSS Q8, BPH Impact Index (BII) and generic QOL using questionnaires like EuroQOL. This study included 1,838 BPE patients and 1,246 patients were evaluable at the end of 24 months. The data showed that LUTS/BPE patients previously treated with medication had significantly impaired QOL in patients in a manner comparable to other chronic diseases after 5-years from the onset of symptoms. In LUTS/BPE individuals, earlier intervention with minimally invasive surgical techniques should be considered that do not exhibit a significant enhancement in QOL with medical therapy.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries